AI Article Synopsis
- Tissue engineered constructs need to be tested for effectiveness in both normal and osteoporotic bone, with rats commonly used as models for osteoporosis studies.
- A new standardized critical size defect model was developed in ovariectomised and normal Wistar rats, creating a 5 mm defect in the femur using a stable PEEK plate system.
- The study confirmed that the model was effective for evaluation, as untreated defects failed to heal, highlighting its utility for testing new tissue engineering approaches in various bone conditions.
Article Abstract
Tissue engineered constructs should be tested for their efficacy not only in normal but also in osteoporotic bone. The rat is an established animal model for osteoporosis and is used often for bone healing studies. In this study a defined and standardized critical size defect model in the rat suitable for screening new tissue engineered constructs in normal and osteoporotic bone is described and validated. Normal and ovariectomised Wistar rats received a unilateral middiaphyseal 5 mm defect in the femur, which was instrumented with a radiolucent PEEK plate fixed with angular stable titanium screws and left untreated. All animals were euthanized eight weeks after defect surgery and the bone healing was evaluated using radiographs, computed tomography measurements, and histology. The developed fixation system provided good stability, even in osteoporotic bone. The implants and ancillary instruments ensured consistent and facile placement of the PEEK plates. The untreated defects did not heal without intervention making the model a well-defined and standardized critical size defect model highly useful for evaluating tissue engineered solutions in normal and osteoporotic bone.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3967594 | PMC |
| http://dx.doi.org/10.1155/2014/348635 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Parathyroid hormone levels following denosumab vs. zoledronic acid therapy for osteoporosis.
Bone
January 2025
Research Institute, Meir Medical Center, Kfar Saba, Israel.
The objective of this retrospective, database study was to characterize the rate, magnitude and timeline of increases in parathyroid hormone (PTH) levels post-denosumab (DMAb) vs. zoledronic acid (ZA) injection in patients with osteoporosis and near normal baseline PTH. Included were osteoporotic females, ≥50 years, initiating treatment with 60 mg DMAb or 5 mg ZA.
View Article and Find Full Text PDFEvaluation of lumbar vertebral bone quality using T1-weighted MRI: Can it differentiate normal, osteopenia, and osteoporosis?
J Clin Densitom
January 2025
University of Health Sciences, Umraniye Training and Research Hospital, Department of Radiology, Istanbul, Turkey.
Background: Osteoporosis, a systemic skeletal disease characterized by low bone mass and microarchitectural deterioration, poses a significant public health challenge globally. While the gold standard for diagnosing osteoporosis is dual-energy X-ray absorptiometry (DXA), its use is limited by factors like spinal deformities and artifacts. This study aims to explore the potential of routine T1-weighted MRI sequences in predicting osteopenia and osteoporosis through the vertebral bone signal (VB) to cerebrospinal fluid signal (CSF) ratio.
View Article and Find Full Text PDFBody composition of older adults with normal body mass index. Cross-sectional analysis of the Toulouse Frailty clinic.
J Frailty Aging
February 2025
IHU HealthAge, Frailty Clinic, Toulouse University Hospital, Gérontopôle, La Cité de la Santé, Hôpital La Grave, Place Lange, Toulouse 31059, France. Electronic address:
Background: Body mass index (BMI) determines general corpulence and health, whatever age, sex or clinical background. Normal BMI (18.5-24.
View Article and Find Full Text PDFOsteoporotic thoracolumbar spine fractures in the elderly: alterations in GNRI and BMP-2 in delayed union and associated factors.
Am J Transl Res
December 2024
Department of Orthopaedics, Liyang Hospital of Chinese Medicine Changzhou 213300, Jiangsu, China.
Objective: To investigate the alterations in the Geriatric Nutritional Risk Index (GNRI) and bone morphogenetic protein 2 (BMP-2) levels and identify associated factors in older adults with delayed union of osteoporotic thoracolumbar spine fractures.
Methods: From June 2021 to June 2023, 139 elderly patients with osteoporotic thoracolumbar spine fractures were selected and divided into a delayed group and a normal group according to the fracture healing status at 6 months postoperatively. GNRI and BMP-2 levels were assessed in both cohorts.
Fracture Prevention with Infrequent Zoledronate in Women 50 to 60 Years of Age.
N Engl J Med
January 2025
From the Department of Medicine, University of Auckland, Auckland, New Zealand (M.J.B., Z.N., A.M., C.G., V.P., B.M., A.G., I.R.R., G.G., A.H.); the Department of Psychology, Stanford University, Stanford, CA (C.G.); and the Department of Radiology, Starship Hospital, Auckland, New Zealand (S.B.).
Background: Zoledronate prevents fractures in older women when administered every 12 to 18 months, but its effects on bone density and bone turnover persist beyond 5 years. Whether infrequent zoledronate administration would prevent vertebral fractures in early postmenopausal women is unknown.
Methods: We conducted a 10-year, prospective, double-blind, randomized, placebo-controlled trial involving early postmenopausal women (50 to 60 years of age) with bone mineral density T scores lower than 0 and higher than -2.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!